PINP as a biological response marker during teriparatide treatment for osteoporosis

Osteoporosis International

Volumn 25, Issue 9, 2014, Pages 2159-2171

  Krege, J H ^a   Lane, N E ^b   Harris, J M ^c   Miller, P D ^d,e  

^a Lilly USA ^*  (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e Health Sciences Center and Colorado Center for Bone Research   (United States)

Author keywords

Anabolics; Biochemical markers of bone turnover; Osteoporosis; PINP; Teriparatide

Indexed keywords

PARATHYROID HORMONE[1-34]; PLACEBO; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; PROCOLLAGEN TYPE I N PROPEPTIDE; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; BONE DENSITY CONSERVATION AGENT; PEPTIDE FRAGMENT; PROCOLLAGEN; PROCOLLAGEN TYPE I N-TERMINAL PEPTIDE;

BONE SCINTISCANNING; HUMAN; MORPHOMETRICS; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; OUTCOME ASSESSMENT; POSTMENOPAUSE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT RESPONSE; BLOOD; BONE DEVELOPMENT; DRUG MONITORING; FEMALE; OSTEOPOROSIS, POSTMENOPAUSAL; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; TREATMENT OUTCOME;

BIOMARKERS; BONE DENSITY CONSERVATION AGENTS; DRUG MONITORING; FEMALE; HUMANS; OSTEOGENESIS; OSTEOPOROSIS, POSTMENOPAUSAL; PEPTIDE FRAGMENTS; PROCOLLAGEN; TERIPARATIDE; TREATMENT OUTCOME;

EID: 84906303588     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-014-2646-0     Document Type: Review

References (68)

1. Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344(19):1434-1441 (Pubitemid 32402100)
2. Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF (2003) Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 18(11):1932-1941 (Pubitemid 37377441)
3. Lindsay R, Cosman F, Zhou H et al (2006) A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide. J Bone Miner Res 21(3):366-373
4. Keaveny TM, Donley DW, Hoffmann PF, Mitlak BH, Glass EV, San Martin JA (2007) Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis. J Bone Miner Res 22(1):149-157 (Pubitemid 46032608)
5. Graeff C, Chevalier Y, Charlebois M et al (2009) Improvements in vertebral body strength under teriparatide treatment assessed in vivo by finite element analysis: results from the EUROFORS study. J Bone Miner Res 24(10):1672-1680
6. Prevrhal S, Krege JH, Chen P, Genant H, Black DM (2009) Teriparatide vertebral fracture risk reduction determined by quantitative and qualitative radiographic assessment. Curr Med Res Opin 25(4):921-928
7. Krege JH, Wan X (2012) Teriparatide and the risk of nonvertebral fractures in women with postmenopausal osteoporosis. Bone 50(1):161-164
8. FORTEO® (teriparatide [rDNA origin] injection) for subcutaneous USPDI. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aae667c5-381f-4f92- 93df-2ed6158d07b0. Accessed 4 June 2013
9. Curtis JR, Cai Q, Wade SW et al (2013) Osteoporosis medication adherence: physician perceptions vs. patients' utilization. Bone 55(1):1-6
10. International Society of Clinical Densitometry. 2007 Official positions and pediatric official positions of the International Society for Clinical Densitometry, West Hartford, CT. http://www.ISCD.org. Accessed 20 September 2012
11. Bonnick SL, Lee Shulman L (2006) Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both? Am J Med 119(4A):25S-31S
12. Vasikaran S, Eastell R, Bruyère O et al (2011) Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 22(2):391-420
13. Bauer D, Krege J, Lane N et al (2012) National bone health alliance bone turnover marker project: current practices and the need for US harmonization, standardization, and common reference ranges. Osteoporos Int 23(10):2425-2433
14. Civitelli R, Armamento-Villareal R, Napoli N (2010) Bone turnover markers: understanding their value in clinical trials and clinical practice. Osteoporos Int 20(6):843-851
15. Delmas PD, Vrijens B, Roux C et al (2013) A reinforcement message based on bone turnover marker response influences long-term persistence with risedronate in osteoporosis: the IMPACT study. J Bone Miner Res 18:S374
16. International Osteoporosis Foundation. The adherence gap: why osteoporosis patients don't continue with treatment. http://www.iofbonehealth. org/sites/default/files/PDFs/adherence-gap-report-2005.pdf. Accessed 22 May 2013
17. Eastell R, Krege JH, Chen P, Glass EV, Reginster JY (2006) Development of an algorithm for using PINP to monitor treatment of patients with teriparatide. Curr Med Res Opin 22(1):61-66 (Pubitemid 43106908)
18. Terreni A, Pezzati P (2012) Biochemical markers in the follow-up of the osteoporotic patients. Clin Cases Min Bone Metab 9(2):80-84
19. Orion Diagnostica. UniQ™ PINP RIA: intact N-terminal propeptide of type I procollagen radioimmunoassay kit. January 2008. Catalogue Number 67034. http://us.idsplc.com/en-us/products/product.php?id=6309. Accessed 3 June 2013
20. Lodish H, Berk A, Zipursky SL, Matsudaira P, Baltimore D, Darnell J (2000) Collagen: the fibrous proteins of the matrix. In: Molecular cell biology, 4th edn. WH Freeman, New York, Table 22-3. http://www.ncbi.nlm.nih.gov/books/ NBK21475/. Accessed 2 December 2013
21. Melkko J, Kauppilla S, Niemi S, Risteli L, Haukipuro K, Jukkola A, Risteli J (1996) Immunoassay for intact amino-terminal propeptide of human type I procollagen. Clin Chem 42(6):947-954
22. Chen P, Satterwhite JH, Licata AA et al (2005) Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 20(6):962-970 (Pubitemid 40712820)
23. Chen P, Glass EV, Krege JH. Early changes in bone turnover markers (BTMs) predict vertebral strength in teriparatide- or alendronate-treated postmenopausal women with osteoporosis [abstract]. In: ENDO 2007 Program & Abstracts, June 2007, Endocrine Society, Toronto, Canada
24. Chen P, Miller PD, Delmas PD, Misurski DA, Krege JH (2006) Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. J Bone Miner Res 21(11):1785-1790 (Pubitemid 46141234)
25. Naylor K, Eastell R (2012) Bone turnover markers: use in osteoporosis. Nat Rev Rheumatol 8(7):379-389
26. United States Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry: qualification process for drug development tools. Draft guidance, October 2010. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UC<230597.pdf. Accessed 22 May 2013
27. Miller PD (2012) Bone strength and surrogate markers: the 1st, 2nd, and 3rd fiddle. J Bone Miner Res 27(8):1623-1626
28. Immunodiagnosticsystems. Fully automated intact PINP. http://www.pantec.it/files/IDS-iSYS-Intact-PINP-IS-4000.pdf. Accessed 4 June 2013
29. Roche Diagnostics. http://www.roche.com/products/product-list.htm?region= us&type=diagnostics&id=24. Accessed 22 May 2013
30. USCN Life Science. ELISA kit. http://www.uscnk.us/elisa/ELISA-Kit-for- Human-Procollagen-I-N-Terminal-Propeptide-PINP-1354. htm. Accessed 3 June 2013
31. Koivula M, Risteli L, Risteli J (2012)Measurement of aminoterminal propeptide of type 1 procollagen (P1NP) in serum. Clin Biochem 45(12):920-927
32. Cavalier E, Lukas P, Ferrante N, Rousselle O, Carlisi A, Delanaye P (2013) Difference between total and intact assays for N-terminal propeptide of type I procollagen (PINP) Determination in renal impaired patients. OC 29. In: EuroMEdLab 2013 - Scientific sessions. 20th IFCC-EFLM European congress of clinical chemistry and laboratory medicine (EuroMedLab) and 45th congress of the Italian society of clinical biochemistry and clinical molecular biology (SIBioC), 19-23 May 2013, Milan, Italy. Biochimica Clinica 37:S42. http://www.sibioc.it/upload/bc/37/SS/915-7-83-Scientific-Sessions.pdf. Accessed 22 May 2013
33. Insogna K, Simpson C (2010) A new automated method for measuring intact amino-terminal propeptide of type 1 procollagen (PINP). J Bone Miner Res 25(Suppl 1). http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx? aid=1e5dd592-c08c-4692-a19b-6a7927a93888. Accessed 13 May 2013
34. Richardson J, Griffiths K, Bennett AH, Garrity ML, Barnes AK. A new automated intact amino-terminal propeptide of type I procollagen (PINP) assay*on the IDS-iSYS analyser. http://www.idsplc.com/z-includes/z-assets/ asset-file.php?id=9237. Accessed 5 August 2013
35. McClung M, San Martin J, Miller PD et al (2005) Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 165(15):1762-1768 (Pubitemid 41138965)
36. Anastasilakis AD, Goulis DG, Polyzos SA et al (2008) Head to head comparison of risedronate vs. teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomized trial. Int J Clin Pract 62(6):919-924 (Pubitemid 351691499)
37. Recker RR, Marin F, Ish-Shalom S et al (2009) Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis. J Bone Miner Res 24(8):1358-1368
38. Miyauchi A, Matsumoto T, Sugimoto T, Tsujimoto M, Warner MR, Nakamura T (2010) Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study; 12-month, randomized, placebo-controlled, double-blind and 12-month open-label phases. Bone 47(3):493-502
39. Tsujimoto M, Chen P, Miyauchi A, Sowa H, Krege JH (2011) PINP as an aid for monitoring patients treated with teriparatide. Bone 48(4):798-803
40. Blumsohn A, Marin F, Nickelsen T et al (2011) Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide. Osteoporos Int 22(6):1935-1946
41. Boonen S, Marin F, Obermayer-Pietsch B et al (2008) Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 93(3):852-860 (Pubitemid 351398563)
42. Ettinger B, San Martin J, Crans G, Pavo I (2004) Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 19(5):745-751 (Pubitemid 41094385)
43. Middleton ET, Steel SA, Doherty SM (2007) The effect of prior bisphosphonate exposure on the treatment response to teriparatide in clinical practice. Calcif Tissue Int 81(5):335-340 (Pubitemid 350077202)
44. Miller PD, Delmas PD, Lindsay R et al (2008) Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab 93:3785-3793
45. Deal C, Omizo M, Schwartz EN et al (2005) Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res 20(11):1905-1911 (Pubitemid 41532775)
46. Cosman F, Wermers RA, Recknor C et al (2009) Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent. J Clin Endocrinol Metab 94(10):3772-3780
47. Devogelaer JP, Adler RA, Recknor C et al (2010) Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis. J Rheumatol 37(1):141-148
48. Saag KG, Shane E, Boonen S et al (2007) Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357(20):2028-2039 (Pubitemid 350106710)
49. Saag KG, Zanchetta JR, Devogelaer JP et al (2010) Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum 60(11):3346-3355
50. Burshell AL, Moricke R, Correa-Rotte R et al (2010) Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate. Bone 46(4):935-939
51. Langdahl BL, Marin F, Shane E et al (2009) Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status. Osteoporos Int 20(12):2095-2104
52. Farahmand P, Marin F, Hawkins F et al (2013) Early changes in biochemical markers of bone formation during teriparatide therapy correlate with improvements in vertebral strength in men with glucocorticoid-induced osteoporosis. Osteoporos Int 24:2971-2981
53. Glüer CC, Marin F, Ringe JD et al (2013) Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial. J Bone Miner Res 28(6):1355-1368
54. Cohen A, Stein EM, Recker RR et al (2013) Teriparatide for idiopathic osteoporosis in premenopausal women: a pilot study. J Clin Endocrinol Metab 98(5):1971-1981, Mar 29Epub 2013
55. Glover SJ, Eastell R, McCloskey EV et al (2009) Rapid and robust response of biochemical markers of bone formation to teriparatide therapy. Bone 45(6):1503-1508
56. Moore AE, Blake GM, Taylor KA et al (2010) Assessment of regional changes in skeletal metabolism following 3 and 18 months of teriparatide treatment. J Bone Miner Res 25(5):960-967
57. Dempster DW, Zhou H, Recker RR et al (2012) Skeletal histomorphometry in subjects on teriparatide or zoledronic acid therapy (SHOTZ) study: a randomized controlled trial. J Clin Endocrinol Metab 97(8):2799-2808
58. Niimi R, Kono T, Nishihara A et al. (2013) An algorithm using the early changes in PINP to predict the future BMD response for patients treated with daily teriparatide. Osteoporos Int 2013 Jun 29 [Epub ahead of print]. doi 10.1007/s00198-013-2426-2
59. Hannon R, Blumsohn A, Naylor K, Eastell R (1998) Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability. J Bone Miner Res 13(7):1124-1133 (Pubitemid 28311780)
60. Krege JH, Blumsohn A, Nickelsen TA et al (2006) Testing an algorithm for using PINP to monitor treatment of patients with teriparatide (abstract). J Bone Miner Res 21(Suppl 1):S302
61. Cosman F, Keaveny TM, Kopperdahl D et al (2013) Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene. J Bone Miner Res 28(6):1328-1336
62. Tsai JN, Uihlein AV, Lee H et al (2013) Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomized trial. Lancet 382:50-56
63. Lane NE, See K, Warner MR, Krege JH (2010) Algorithm for using a bone formation marker PINP to monitor the response to teriparatide (TPTD) in patients with glucocorticoid-induced osteoporosis (GIO). Arthritis Rheum 62(Suppl 10):957
64. Funck-Brentano T, Biver E, Chopin F et al (2011) Clinical utility of serum bone turnover markers in postmenopausal osteoporosis therapy monitoring: a systematic review. Semin Arthritis Rheum 41(2):157-169
65. Kung AW, Rachman IA, Adam JM et al (2009) Impact of bone marker feedback on adherence to once monthly ibandronate for osteoporosis among Asian postmenopausal women. Int J Rheum Dis 12(3):216-224
66. Delmas PD, Eastell R, Garnero P et al (2000) The use of biochemical markers of bone turnover in osteoporosis Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int 11(Suppl 6):S2-S17
67. National Osteoporosis Foundation (2013) Clinician's guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation, Washington, DC
68. Morris H (2013) The need for standardisation of bone marker assays. SY 69. In: EuroMEdLab 2013 - scientific sessions. 20th IFCC-EFLM European congress of clinical chemistry and laboratory medicine (EuroMedLab) and 45th congress of the Italian society of clinical biochemistry and clinical molecular biology (SIBioC), 2013 19-23 May, Milan, Italy. Biochimica Clinica 37:S41. http://www.sibioc.it/upload/bc/37/SS/915-7-83-Scientific-Sessions.pdf. Accessed 22 May 2013